Daniel Copell Watson
Known title: Executive VP Americas SalesCIK: 0001860764
Associated companies
Transaction History
| SKIN | ▲ Buy | Grant | 243,506 | — | 4/9/2024 | View on chart |
| SKIN | ▼ Sell | Tax Withholding | 11,212 | $42K | 4/5/2024 | View on chart |
| SKIN | ▼ Sell | Tax Withholding | 6,356 | $24K | 3/1/2024 | View on chart |
| SKIN | ▼ Sell | Tax Withholding | 10,633 | $32K | 2/4/2024 | View on chart |
| SKIN | ▲ Buy | Grant | 156,250 | — | 11/29/2023 | View on chart |
| SKIN | ▲ Buy | Grant | 94,265 | — | 4/5/2023 | View on chart |
| SKIN | ▲ Buy | Grant | 17,560 | — | 3/1/2023 | View on chart |
| SKIN | ▼ Sell | Tax Withholding | 8,972 | $116K | 2/4/2023 | View on chart |
| SKIN | ▲ Buy | Grant | 77,835 | — | 2/4/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
SkinHealth Systems Expands SkinStylus MicroSystem to Europe
SkinHealth Systems announced that its SkinStylus® SteriLock® MicroSystem will now be available in European markets. The move expands the company’s footprint beyond North America and could broaden its customer base. The product is a sterilization platform used in dermatology. The news comes as the stock trades near its 52‑week low, but the expansion may support future growth.
SkinHealth Systems Expands SkinStylus MicroSystem to Europe. SkinHealth Systems announced that its SkinStylus® SteriLock® MicroSystem will now be available in European markets. The move expands the company’s footprint beyond North America and could broaden its customer base. The product is a sterilization platform used in dermatology. The news comes as the stock trades near its 52‑week low, but the expansion may support future growth.